Abstract
The perimenopausal period is the age of the highest spiritual and intellectual development of a woman; therefore, neurovegetative and psycho-emotional disorders of this period acquire a special medical and social value and require the search for effective and safe methods of their correction. The objective: to evaluate the effectiveness of the drug Noofen® in women with mild to moderate menopausal disorders in the perimenopausal period. Materials and methods. A total of 51 women were examined in the perimenopausal period: I main group – 20 patients with a low degree of CS, II main group – 16 women with menopausal disorders of moderate severity; the control group consisted of 15 healthy women. For the correction of perimenopausal disorders, the drug Noofen® («Olainfarm» Joint-Stock Company, Latvia) was used according to the scheme proposed by us. The effectiveness of non-hormonal correction of CS symptoms was assessed by the dynamics of the modified menopausal index, the characteristics of the hormonal status and the results of psychodiagnostic examination. Results. In women of the main groups, neurovegetative (14.5±2.6 and 26.6±4.2 points in the first and second groups of observation) and psycho-emotional disorders (4.9±1.3 and 11.2±1.6 points) prevailed. respectively). Hormone levels (FSH, E2, PRL) corresponded to perimenopausal values, but were significantly different from those of the control group. Identified individual-personal properties of women with the CS, in particular introversion and emotional instability. A comparative analysis on the Spielberg-Khanin scales showed that more than half (55.0%) in the first main group and the majority (81.25%) of women in the second main group versus 33.35% in the control group (p<0.05), a high level of personal anxiety was diagnosed; the average level of situational anxiety was highest among women in group II – 54.83±6,0 points versus 43.2±5.3 points in the first group and 36.3±4.8 points in patients without menopausal disorders (p<0.05). In 24 (77.42%) women of the main group, sexual dysfunction was detected, while its degree was greatest with moderately severe climacteric disorders. Non-hormonal correction of perimenopausal disorders with the help of Noofen® helped reduce the total menopausal index and led to the disappearance of clinical manifestations of CS in 10 (50,0%) women in the first and 6 (37.5%) in the second groups. A significant decrease in the levels of personal and reactive anxiety during therapy showed a pronounced tranquilizing effect of the GAMA derivative and beta-phenylethylamine. The improvement of psycho-emotional and sexual states contributed to the improvement of the main indicators of the quality of life of patients in the perimenopausal period. Conclusion. The results of the study showed the high efficacy of the Noofen® preparation, which can be recommended for non-hormonal correction of neurovegetative and psychoemotional disorders in women in the perimenopausal period. Key words: perimenopause, menopausal syndrome, menopausal index, Noofen®, anxiety, sexual dysfunction, quality of life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
